Merck finishes animal vaccine plant overhaul

Merck ($MRK) has completed its expansion and renovation of an Elkhorn, NE, animal vaccine plant and will begin transferring researchers from its Delaware site to the newly improved facility. The company has spent $13.5 million renovating the plant, adding a high-speed vaccine vial filling line and disinfection chambers. Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.